Breaking News Headlines Today | Ground News

See every side of every news story

Express Pharma image

News from Express Pharma

Ground News rates Express Pharma’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Express Pharma’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Express Pharma

Where is Express Pharma located?Express Pharma's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Express Pharma News

Eli Lilly announces $6.5B manufacturing plant in Houston, boosting investment from initial proposal — REUTERS / pwu404

Eli Lilly · Houston

Eli Lilly announces $6.5B manufacturing plant in Houston, boosting investment from initial proposal

90% Center coverage: 21 sources

Sai Life Sciences Boosts Veterinary API Production with New Facility

Pharma · Bidar

Sai Life Sciences Boosts Veterinary API Production with New Facility

50% Center coverage: 6 sources

Sai Life Sciences has launched Unit VI, a state-of-the-art facility in Bidar, India, for veterinary API production. This expansion aims to meet the rising global demand for veterinary medicines, utilizing advanced technologies and sustainable practices. The facility aligns with their vision of enhancing niche pharmaceutical offerings.See the Story

New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies

Multiple Sclerosis · Barcelona

New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies

ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after breakthrough disease* on fingolimod or fumarate-based therapies1Following switch to Kesimpta, over 90% of people…See the Story

Breaking News Topics Related to Express Pharma